| 10766881 |
2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases |
Steven W. Andrews, Adam Cook, Indrani W. Gunawardana, Kevin W. Hunt, Andrew T. Metcalf +3 more |
2020-09-08 |
| 10724102 |
Point mutations in TRK inhibitor-resistant cancer and methods relating to the same |
Nisha Nanda, Joshua H. Bilenker, Gabrielle R. Kolakowski, Barbara J. Brandhuber, Steven W. Andrews |
2020-07-28 |
| 10688100 |
Macrocylic compounds as ROS1 kinase inhibitors |
Steven W. Andrews, Julia Haas, Gabrielle R. Kolakowski |
2020-06-23 |
| 10689377 |
KRas G12C inhibitors |
Laurence E. Burgess, Mark Joseph Chicarelli, James Gail Christensen, Adam Cook, Jay Bradford Fell +7 more |
2020-06-23 |
| 10655186 |
Point mutations in TRK inhibitor-resistant cancer and methods relating to the same |
Nisha Nanda, Joshua H. Bilenker, Gabrielle R. Kolakowski, Barbara J. Brandhuber, Steven W. Andrews |
2020-05-19 |
| 10633381 |
KRas G12C inhibitors |
Laurence E. Burgess, Mark Joseph Chicarelli, James Gail Christensen, Jay Bradford Fell, John P. Fischer +11 more |
2020-04-28 |
| 10555944 |
Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors |
Steven W. Andrews, Sean Aronow, Barbara J. Brandhuber, Adam Cook, Julia Haas +9 more |
2020-02-11 |